FEIBA safety and tolerability profile

Haemophilia

Volumn 12, Issue SUPPL. 5, 2006, Pages 14-19

  Gomperts, E D ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b NONE   (United States)

Author keywords

Bypassing therapy; Clinicalsafety; FEIBA; Hemophilia A and B; Viral safety

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9 CONCENTRATE; FEIBA VH; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANAPHYLAXIS; ANTIBODY TITER; ARTICLE; BLEEDING; BLOOD ANALYSIS; BLOOD DONOR; BRONCHOSPASM; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE TIME EFFECT RELATION; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART INFARCTION; HEAT TREATMENT; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFECTION RISK; MUSCLE BLEEDING; NEPHROTIC SYNDROME; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PATIENT SAFETY; PERIOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SEPSIS; SINGLE DRUG DOSE; SKIN BLEEDING; SKIN INFECTION; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; URTICARIA; VAPORIZATION; VIRUS DETECTION; VIRUS INACTIVATION; VIRUS INFECTION;

EID: 33750373189     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01380.x     Document Type: Article

References (35)

1. DiMichele D. Inhibitors: Resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
2. Glomstein A, Gronhaug S, Tjonnfjord G. Home treatment with FEIBA®, the Norwegian experience [abstract]. Haemophilia 2002; 8: 540-1. Abstract 12 PO 33.
3. Hilgartner M, Aledort L, Andes A, Gill J, the FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990; 30: 626-30.
4. Hilgartner MW, Makipernaa A, DiMichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
5. Hilgartner MW, Knatterud GL, the FEIBA Study Group. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983; 61: 36-40.
6. Holme PA, Brosstad F, Tjonnfjord GE. Acquired haemophilia: Management of bleeds and immune therapy to eradicate autoantibodies. Haemophilia 2005; 11: 510-5.
7. Negrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P, the French FEIBA Study Group. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. Thromb Haemost 1997; 77: 1113-9.
8. Sallah S. Treatment of acquired haemophilia with factor eight inhibitor bypassing activity. Haemophilia 2004; 10: 169-73.
9. Valentino L. FEIBA prophylaxis in hemophilia A patients with inhibitors results in 95% reduction in bleeding episodes. Poster presented at: XXVI International Congress of the World Federation of Hemophilia; October 17-21, 2004; Bangkok, Thailand.
10. FEIBA VH [package insert]. Westlake Village, CA: Baxter Healthcare Corporation, 2000.
11. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004; 10: 10-6.
12. Waytes AT, Igel H, Zerlauth G, Wappler N, Lee M, Schwarz O. A safer plasma supply from remunerated donors - "The Immuno/Community Bio-Resources experiment". Dev Biol (Basel) 2000; 102: 37-51.
13. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996;334: 1685-90.
14. Plasma Protein Therapeutics Association. Parvovirus B-19 standard. Available at: http://www.plasmatherapeutics.org/en/ qualitysafety_qseal_b19.cfm. Accessed April 20, 2006.
15. Dorner F, Barrett N. Viral inactivation and partitioning in the manufacture of coagulation factor concentrates. Hämostaseologie 1996; 16: 282-285.
16. Data on file. Baxter A. G.
17. Gomperts E, Warrier I, Negrier C et al. Tolerability of FEIBA treatment in patients with inhibitors [abstract]. Haemophilia 2004; 10: 57-8. Abstract 12 PO 33.
18. Negrier C, the French FEIBA Study Group. FEIBA VH in home treatment - a 3-year prospective experience [abstract]. Haemophilia 1998; 4: 238. Abstract 330.
19. Tjonnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: The updated Norwegian experience. Haemophilia 2004; 10: 41-5.
20. Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981; 305: 717-21.
21. DiMichele D, Negrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006; 12: 352-62.
22. Escuriola Ettingshausen C, Martinez-Saguer I, Funk MB et al. Long-term prophylaxis with FEIBA® in patients with high-responding inhibitors [abstract]. J Thromb Haemost 2003; 1 (Suppl 1): Abstract P1628.
23. Ewenstein B, Giangrande P, Morfini M et al. Evaluation of FEIBA for prophylaxis in patients with inhibitors. Poster presented at: XXVI International Congress of the World Federation of Hemophilia; October 17-21, 2004; Bangkok, Thailand.
24. Boggio LN, Green D. Acquired hemophilia. Rev Clin Exp Hematol 2001; 5: 389-404; quiz following 431.
25. Goudemand J. Treatment of bleeding episodes occurring in patients with acquired haemophilia with FEIBA: The French experience. Poster presented at: 26th World Federation of Hematology Congress; October 17-21, 2004; Bangkok, Thailand.
26. Aledort LM. Is the incidence and prevalence of inhibitors greater with recombinant products? Yes. J Thromb Haemost 2004; 2: 861-2.
27. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.
28. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 2006; 295: 293-8.
29. Green D. Complications associated with the treatment of haemophiliacs with inhibitors. Haemophilia 1999; 5: 11-7.
30. Ewing N. Anamnestic responses in hemophilia patients with inhibitors on continuous prophylaxis with factor eight inhibitor bypassing activity, vapor heated (FEIBA VH) [abstract]. J Thromb Haemost 2005; 3: (Suppl 1): abstract P2036.
31. Jadhav M, Warrier I. Anaphylaxis in patients with hemophilia. Semin Thromb Hemost 2000; 26: 205-8.
32. Lusher JM. Inhibitor antibodies to factor VIII and factor IX: management. Semin Thromb Hemost 2000; 26: 179-88.
33. Sawamoto Y, Shima M, Yamamoto M et al. Measurement of anti-factor IX IgG subclasses in haemophilia B patients who developed inhibitors with episodes of allergic reactions to factor IX concentrates. Thromb Res 1996; 83: 279-86.
34. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998; 4: 574-6.
35. Ewenstein BM, Takemoto C, Warrier I et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997; 89: 1115-6.